[go: up one dir, main page]

AR046254A1 - Productos farmaceuticos estables - Google Patents

Productos farmaceuticos estables

Info

Publication number
AR046254A1
AR046254A1 ARP040102429A ARP040102429A AR046254A1 AR 046254 A1 AR046254 A1 AR 046254A1 AR P040102429 A ARP040102429 A AR P040102429A AR P040102429 A ARP040102429 A AR P040102429A AR 046254 A1 AR046254 A1 AR 046254A1
Authority
AR
Argentina
Prior art keywords
stable pharmaceutical
formoterol
tartrate
pharmaceutical products
salt
Prior art date
Application number
ARP040102429A
Other languages
English (en)
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of AR046254A1 publication Critical patent/AR046254A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Un producto farmacéutico estable que comprende: a) un dispositivo inhalador de polvo seco; b) una cantidad efectiva de un material sorbente; c) una composición farmacéutica en dicho dispositivo que comprende: i) la sal R,R- formoterol L-tartrato; y ii) ciclosonida; y d) un envase sellado que posee un volumen contenido en el cual se encuentra dicho dispositivo, dicho material sorbente y la composición farmacéutica mencionada. Reivindicación 2: El producto farmacéutico estable de la reivindicación 1, en el cual dicha sal R,R-formoterol L-tartrato es la sal cristalina R,R-formoterol L-tartrato.
ARP040102429A 2003-07-08 2004-07-08 Productos farmaceuticos estables AR046254A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0315889.6A GB0315889D0 (en) 2003-07-08 2003-07-08 Stable pharmaceutical products

Publications (1)

Publication Number Publication Date
AR046254A1 true AR046254A1 (es) 2005-11-30

Family

ID=27741730

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040102429A AR046254A1 (es) 2003-07-08 2004-07-08 Productos farmaceuticos estables

Country Status (10)

Country Link
US (2) US7947744B2 (es)
EP (1) EP1643980B1 (es)
JP (1) JP5602983B2 (es)
AR (1) AR046254A1 (es)
AU (1) AU2004255026A1 (es)
CA (1) CA2531646C (es)
ES (1) ES2428138T3 (es)
GB (1) GB0315889D0 (es)
TW (1) TW200526275A (es)
WO (1) WO2005004853A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (en) 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
US8214752B2 (en) 2006-09-29 2012-07-03 Sharp Laboratories Of America, Inc. Systems and methods for dynamically generating user interfaces for controlling a device with a client side filter
US20100063016A1 (en) * 2007-02-19 2010-03-11 Cipla Limited Pharmaceutical Combinations
CA2716124A1 (en) * 2008-02-20 2009-08-27 Boehringer Ingelheim International Gmbh Powder inhalers
US20090235929A1 (en) * 2008-03-19 2009-09-24 Marc Egen Powder inhalers
EP4403231A3 (en) 2009-02-26 2024-10-23 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
KR20120024562A (ko) * 2009-04-24 2012-03-14 히사미쓰 세이야꾸 가부시키가이샤 첩부제 수용 포장 백, 및 첩부제의 보존 방법
AU2009100698B4 (en) * 2009-07-17 2010-04-15 Astrazeneca Ab Combination
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
TR201007250A2 (tr) * 2010-09-01 2012-03-21 Bi̇lgi̇ç Mahmut Selobioz içeren formülasyon.
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
MA40027A (fr) * 2014-06-18 2015-12-23 Cipla Ltd Composition pharmaceutique comprenant un bêta-2 agoniste et un agent anticholinergique

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3166396D1 (en) * 1980-02-27 1984-11-08 Tate & Lyle Plc Crystalline glucose and process for its production
US4816445A (en) * 1984-06-21 1989-03-28 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Crystalline alpha-maltose
US5192528A (en) * 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
JP2518646B2 (ja) * 1987-05-29 1996-07-24 株式会社 林原生物化学研究所 マルト−ス粉末の製造方法
GR1001529B (el) * 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
AU650953B2 (en) * 1991-03-21 1994-07-07 Novartis Ag Inhaler
US6866839B2 (en) * 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
SE9302777D0 (sv) * 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
DE19541689A1 (de) * 1994-11-14 1996-05-15 Byk Gulden Lomberg Chem Fab Kombinationsarzneimittel
US6040344A (en) * 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
DK1102579T3 (da) * 1998-08-04 2003-07-14 Jago Res Ag Medicinske aerosolformuleringer
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US6352152B1 (en) 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
SE9903995D0 (sv) 1999-11-03 1999-11-03 Astra Ab New combination
GB9928311D0 (en) 1999-11-30 2000-01-26 Novartis Ag Organic compounds
GB0012260D0 (en) * 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
IL152791A0 (en) * 2000-05-23 2003-06-24 Glaxo Group Ltd Aerosol container for formulations of salmeterol xinafoate
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
US20030055026A1 (en) * 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
GB0122031D0 (en) * 2001-09-12 2001-10-31 Pfizer Ltd Use of pde4 inhibitors in a dry powder inhaler
US6472563B1 (en) * 2001-11-09 2002-10-29 Sepracor Inc. Formoterol tartrate process and polymorph
WO2003043905A2 (en) * 2001-11-17 2003-05-30 Aventis Pharma Limited Pharmaceutical product with an adsorbent
GB0207899D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
EP1635844A1 (en) 2003-05-22 2006-03-22 ALTANA Pharma AG Salmeterol and ciclesonide combination
GB0312148D0 (en) 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
EP1635845A1 (en) 2003-06-13 2006-03-22 ALTANA Pharma AG Formoterol and ciclesonide combination
GB0323685D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds
GB0323684D0 (en) 2003-10-09 2003-11-12 Jagotec Ag Improvements in or relating to organic compounds

Also Published As

Publication number Publication date
TW200526275A (en) 2005-08-16
US8288445B2 (en) 2012-10-16
GB0315889D0 (en) 2003-08-13
JP2007526889A (ja) 2007-09-20
JP5602983B2 (ja) 2014-10-08
US7947744B2 (en) 2011-05-24
EP1643980A1 (en) 2006-04-12
AU2004255026A1 (en) 2005-01-20
ES2428138T3 (es) 2013-11-06
US20110064814A1 (en) 2011-03-17
CA2531646A1 (en) 2005-01-20
EP1643980B1 (en) 2013-07-03
CA2531646C (en) 2011-06-07
US20060104917A1 (en) 2006-05-18
WO2005004853A1 (en) 2005-01-20

Similar Documents

Publication Publication Date Title
AR046254A1 (es) Productos farmaceuticos estables
HRP20090516T1 (hr) Formulacija tienopiridinskog inhibitora agregacije trombocita
EA200701913A1 (ru) Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом
IL188494A0 (en) Novel 2,4-dianlinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors
EA200501406A1 (ru) Усовершенствования инъекционного устройства, подобного ручке
AR056243A1 (es) Productos farmaceuticos que comprenden antagonistas de opiodes
BRPI0413277A (pt) composições farmacêuticas de adsorvatos de medicamentos amorfos e materiais que formam microfases lipofìlicas
BRPI0408231A (pt) embalagem compreendendo uma composição detergente
FR2838648B1 (fr) Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
CO5680461A2 (es) Productos farmaceuticos que comprenden bisfosfonatos
AR046319A1 (es) Sal de tiotropio y composiciones farmaceuticas que la contienen.
ZA200701443B (en) Pharmaceutical composition in the form of a gastric-resident tablet containing an active principle
EA201691869A1 (ru) Стабильная комбинированная фармацевтическая композиция
AR046120A1 (es) Fomulaciones fungicidas que contienen cobre
ATE539769T1 (de) Stabile pharmazeutische zusammensetzungen mit carvedilol
DE50104890D1 (de) Vorrichtung zum lagern und mischen pastöser massen
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
EP1880704A4 (en) LABEL, MEDICAL BAG AND STORAGE CONTAINER WITH LABEL
AR043016A2 (es) Un compuesto antimigranico eletriptan y composicion farmaceutica que lo contiene
GB0215016D0 (en) Apparatus to facilitate the burning of bales of packaging material
FR2932064B1 (fr) Paillette pour la conservation d'une dose de substance a base liquide, notamment une substance biologique
FI20021359L (fi) Kuumasaumautuva pakkausmateriaali sekä siitä muodostettu suljettu tuotepakkaus
IL182835A0 (en) Process for and imtermediates in the preparaition of canfosfamide and its salts, pharmaceutical compositions containing some intermediates, and their use as anticancer agents
BRMU8500295U (pt) disposição construtiva em embalagem de medicamentos e cosméticos
TW200505749A (en) Medicine packaging apparatus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal